| D007154 |
Immune System Diseases |
Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both. |
Immune Disorders,Immune System Disorders,Immunologic Diseases,Diseases of Immune System,Immune Diseases,Immunological Diseases,Disease, Immune,Disease, Immune System,Disease, Immunologic,Disease, Immunological,Disorder, Immune System,Immune Disease,Immune Disorder,Immune System Disease,Immune System Disorder,Immunologic Disease,Immunological Disease |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000074322 |
Antineoplastic Agents, Immunological |
Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS. |
Antineoplastic MAbs,Antineoplastics, Monoclonal Antibodies,Antineoplastics, Monoclonal Antibody,MAbs, Antineoplastic,Monoclonal Antibodies, Antineoplastic,Antibodies Antineoplastics, Monoclonal,Antineoplastic Monoclonal Antibodies,Immunological Antineoplastic Agents,Monoclonal Antibodies Antineoplastics,Monoclonal Antibody Antineoplastics |
|
| D000077594 |
Nivolumab |
A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA. |
BMS-936558,MDX-1106,ONO-4538,Opdivo,BMS 936558,BMS936558,MDX 1106,MDX1106,ONO 4538,ONO4538 |
|